Video

Samuele Cortese, MD: Bringing ADHD Researchers Together

Author(s):

Dr. Cortese discusses the current gaps in ADHD treatment.

While the coronavirus disease 2019 (COVID-19) pandemic has forced organizers to replace bustling live conferences with virtual ones, it has also enabled a more inclusive presenter list.

Taking advantage of the ease of the situation, the organizers for last month’s American Professional Society of ADHD and Related Disorders (APSARD) 2021 Annual Conference were able to present a slate of international attention deficit/hyperactivity disorder (ADHD) researchers.

The meeting featured posters and new data presentations from investigators across the globe, including the US, UK, Germany and Japan, who were able to log onto their computer and network with colleagues as opposed to having to fly across the globe at an expense.

One such ADHD researchers was Samuele Cortese, MD, PhD, Professor of Child and Adolescent Psychiatry, University of Southampton.

In an interview with HCPLive®, Cortese explained how important it is to bring an international class of researchers together in the virtual format to share data and discuss best practices in ADHD care.

The fact of the matter is ADHD is likely going to change in the future because of the ongoing pandemic.

Cortese discussed some of the known gaps in how clinicians treat ADHD patients and what could be done in the future to close some of these gaps.

Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
© 2024 MJH Life Sciences

All rights reserved.